Novel molecular strategies against sulfur mustard toxicity;Sülfür mustard toksisitesine karşı yeni moleküler stratejiler

TAF Preventive Medicine Bulletin

Volumn 11, Issue 2, 2012, Pages 229-234

  Kunak, Zeki Ilker ^a   Toygar, Mehmet ^a   Poyrazoglu, Yavuz ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Elazig Military Hospital   (Turkey)

Author keywords

Chemical warfare agent; Epigenetics; Sulfur mustard

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DNA; MUSTARD GAS;

ABSORPTION; ACUTE TOXICITY; CHROMATIN STRUCTURE; DNA DAMAGE; DNA METHYLATION; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG EXPOSURE; EPIGENETICS; HUMAN; LETHALITY; MULTIPLE ORGAN FAILURE; MUSTARD; NONHUMAN; PATHOGENESIS; REVIEW; SULFUR MUSTARD TOXICITY; TOXICITY;

EID: 84859147556     PISSN: 1303734X     EISSN: None     Source Type: Journal    
DOI: 10.5455/pmb.1-1328011599     Document Type: Review

References (61)

1. Smith KJ, Skelton H. Chemical warfare agents: their past and continuing threat and evolving therapies. Part II of II. Skinmed. 2003; 2: 297.
2. Kehe K, Szinicz L. Medical aspects of sulphur mustard poisoning. Toxicology. 2005; 214: 198.
3. Laskin JD, Black AT, Jan YH, et al. Oxidants and antioxidants in sulfur mustard-induced injury. Ann N Y Acad Sci. 2010; 1203: 92.
4. Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007; 23: 303.
5. Korkmaz A, Yaren H, Topal T, Oter S. Molecular targets against mustard toxicity: implication of cell surface receptors, peroxynitrite production, and PARP activation. Arch Toxicol. 2006; 80: 662.
6. Yildirim I, Korkmaz A, Oter S, Ozcan A, Oztas E. Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. Cancer Chemother Pharmacol. 2004; 54: 469.
7. Ozcan A, Korkmaz A, Oter S, Coskun O. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. Arch Toxicol. 2005; 79: 461.
8. Sadir S, Deveci S, Korkmaz A, Oter S. Alpha-tocopherol, beta-carotene and melatonin administration protects cyclophosphamide-induced oxidative damage to bladder tissue in rats. Cell Biochem Funct. 2007; 25: 521.
9. Korkmaz A, Oter S, Deveci S, et al. Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J Urol. 2003; 170: 2498.
10. Oter S, Korkmaz A, Oztas E, Yildirim I, Topal T, Bilgic H. Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats. Urol Res. 2004; 32: 185.
11. Topal T, Oztas Y, Korkmaz A, et al. Melatonin ameliorates bladder damage induced by cyclophosphamide in rats. J Pineal Res. 2005; 38: 272.
12. Ucar M, Korkmaz A, Reiter RJ, et al. Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard. Toxicol Lett. 2007; 173: 124.
13. Korkmaz A, Oter S, Sadir S, et al. Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats. J Urol. 2005; 173: 1793.
14. Yaren H, Mollaoglu H, Kurt B, et al. Lung toxicity of nitrogen mustard may be mediated by nitric oxide and peroxynitrite in rats. Res Vet Sci. 2007; 83: 116.
15. Demicheli V, Quijano C, Alvarez B, Radi R. Inactivation and nitration of human superoxide dismutase SOD by fluxes of nitric oxide and superoxide. Free Radic Biol Med. 2007; 42: 1359.
16. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007; 87: 315.
17. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem. 2001; 276: 29596.
18. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res. 2001; 92: 439.
19. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett. 2003; 140-141: 105.
20. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA. 1998; 95: 5246.
21. Juedes MJ, Wogan GN. Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Mutat Res. 1996; 349: 51.
22. Masuda M, Nishino H, Ohshima H. Formation of 8-nitroguanosine in cellular RNA as a biomarker of exposure to reactive nitrogen species. Chem Biol Interact. 2002; 139: 187.
23. Tamir S, deRojas-Walker T, Wishnok JS, Tannenbaum SR. DNA damage and genotoxicity by nitric oxide. Methods Enzymol. 1996; 269: 230.
24. Yoshie Y, Ohshima H. Nitric oxide synergistically enhances DNA strand breakage induced by polyhydroxyaromatic compounds, but inhibits that induced by the Fenton reaction. Arch Biochem Biophys. 1997; 342: 13.
25. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998; 351: 28.
26. Yermilov V, Yoshie Y, Rubio J, Ohshima H. Effects of carbon dioxide/bicarbonate on induction of DNA single-strand breaks and formation of 8-nitroguanine, 8-oxoguanine and base-propenal mediated by peroxynitrite. FEBS Lett. 1996; 399: 67.
27. Chien YH, Bau DT, Jan KY. Nitric oxide inhibits DNA-adduct excision in nucleotide excision repair. Free Radic Biol Med. 2004; 36: 1011.
28. Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett. 2003; 140-141: 113.
29. Kehe K, Raithel K, Kreppel H, Jochum M, Worek F, Thiermann H. Inhibition of polyADP-ribose polymerase PARP influences the mode of sulfur mustard SM-induced cell death in HaCaT cells. Arch Toxicol. 2008; 82: 461.
30. Korkmaz A, Kurt B, Yildirim I, et al. Effects of polyADP-ribose polymerase inhibition in bladder damage caused by cyclophosphamide in rats. Exp Biol Med Maywood. 2008; 233: 338.
31. Somani SM, Babu SR. Toxicodynamics of sulfur mustard. Int J Clin Pharmacol Ther Toxicol. 1989; 27: 419.
32. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102: 43.
33. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol. 2006; 99: 273.
34. Balali-Mood M, Hefazi M, Mahmoudi M, et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol. 2005; 19: 713.
35. Shohrati M, Peyman M, Peyman A, Davoudi M, Ghanei M. Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan Ocul Toxicol. 2007; 26: 73.
36. Hefazi M, Attaran D, Mahmoudi M, Balali-Mood M. Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol. 2005; 17: 587.
37. Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol. 2005; 5: 1479.
38. Nohmi T, Kim SR, Yamada M. Modulation of oxidative mutagenesis and carcinogenesis by polymorphic forms of human DNA repair enzymes. Mutat Res. 2005; 591: 60.
39. Szabo E, Virag L, Bakondi E, et al. Peroxynitrite production, DNA breakage, and polyADP-ribose polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J Invest Dermatol. 2001; 117: 74.
40. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005; 97: 1498.
41. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16: 6.
42. Bronner C, Chataigneau T, Schini-Kerth VB, Landry Y. The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory. Curr Med Chem. 2007; 14: 2629.
43. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000; 9: 2395.
44. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007; 26: 5310.
45. McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev. 2001; 22: 319.
46. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes. 2005; 54: 1899.
47. McLachlan JA, Burow M, Chiang TC, Li SF. Gene imprinting in developmental toxicology: a possible interface between physiology and pathology. Toxicol Lett. 2001; 120: 161.
48. Bombail V, Moggs JG, Orphanides G. Perturbation of epigenetic status by toxicants. Toxicol Lett. 2004; 149: 51.
49. Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease. Annu Rev Genomics Hum Genet. 2004; 5: 479.
50. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet. 2007; 16(1): R28.
51. Ducasse M, Brown MA. Epigenetic aberrations and cancer. Mol Cancer. 2006; 5: 60.
52. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001; 20: 3139.
53. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16(1): R50.
54. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004; 22: 4632.
55. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet. 2002; 111: 115.
56. Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007; 13: 17.
57. Peedicayil J. Epigenetic therapy--a new development in pharmacology. Indian J Med Res. 2006; 123: 17.
58. Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol. 2005; 19: 297.
59. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med. 2003; 45: 1136.
60. Korkmaz A, Kunak ZI, Paredes SD, Yaren H, Tan DX, Reiter RJ. The use of melatonin to combat mustard toxicity. REVIEW. Neuro Endocrinol Lett. 2008; 29: 614.
61. Korkmaz A, Yaren H, Kunak ZI, et al. Epigenetic perturbations in the pathogenesis of mustard toxicity; hypothesis and preliminary results. Interdiscip Toxicol. 2008; 1: 236.